垂体母细胞瘤的临床结局与并发症
中位诊断年龄11个月,库欣综合征最常见(10例)。中位随访6.7年,9例存活,8例死亡;手术切除范围与生存显著相关,长期神经内分泌管理可获质量生存。
要点
- 垂体母细胞瘤是婴儿罕见肿瘤,多与DICER1综合征相关。
- 库欣综合征最常见,但部分患儿无库欣样体征。
- 手术切除范围与生存显著相关,辅助治疗未显示显著关联。
核心结论
- 垂体母细胞瘤是一种局部破坏性肿瘤,死亡率高。
- 部分患者仅靠手术即可获得长期疾病控制。
- 通过长期神经内分泌管理可能实现质量生存。
研究设计与样本
- 多机构病例系列,来自三级儿科肿瘤中心。
- 报告遗传检测、手术、肿瘤治疗及内分泌支持。
主要发现
- 库欣综合征是最常见表现(10例);7例无库欣样体征(2例ACTH升高,5例ACTH正常或未测)。
- 手术方式包括全/近全切除(7例)、次全切除(9例)和活检(1例);6例接受辅助治疗。
- 中位随访6.7年,9例存活,8例死亡;死亡原因包括早期医学/手术并发症(3例)、脓毒症(1例)、导管相关并发症(1例)、动脉瘤出血(1例)、第二脑肿瘤(1例)和进展(1例)。
- 9例存活者中5例仅接受手术;切除范围与生存显著相关,Ki67标记指数和辅助治疗与生存无显著关联。
关键数值与推荐
- 中位诊断年龄11个月(范围2-24个月)。
- 库欣综合征最常见(10例)。
- 中位随访6.7年,9例存活,8例死亡。
- 切除范围与生存显著相关;Ki67标记指数和辅助治疗与生存无显著关联。
临床怎么用
- 对婴儿库欣综合征或颅内占位需警惕垂体母细胞瘤,并评估DICER1综合征。
- 手术切除是主要治疗手段,切除范围影响生存。
- 长期随访需关注神经内分泌、视觉和神经发育并发症。
局限性
- 部分患儿ACTH未测,临床表现评估可能不完整。
- 辅助治疗方案异质,无法评估具体疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pituitary blastoma is a rare, dysontogenetic hypophyseal tumor of infancy first described in 2008, strongly suggestive of DICER1 syndrome. OBJECTIVE: This work aims to describe genetic alterations, clinical courses, outcomes, and complications in all known pituitary blastoma cases. DESIGN AND SETTING: A multi-institutional case series is presented from tertiary pediatric oncology centers. PATIENTS: Patients included children with pituitary blastoma. INTERVENTIONS: Genetic testing, surgery, oncologic therapy, endocrine support are reported. OUTCOME MEASURES: Outcome measures included survival, long-term morbidities, and germline and tumor DICER1 genotypes. RESULTS: Seventeen pituitary blastoma cases were studied (10 girls and 7 boys); median age at diagnosis was 11 months (range, 2-24 months). Cushing syndrome was the most frequent presentation (n = 10). Cushingoid stigmata were absent in 7 children (2 with increased adrenocorticotropin [ACTH]; 5 with normal/unmeasured ACTH). Ophthalmoplegia and increased intracranial pressure were also observed. Surgical procedures included gross/near-total resection (n = 7), subtotal resection (n = 9), and biopsy (n = 1). Six children received adjuvant therapy. At a median follow-up of 6.7 years, 9 patients were alive; 8 patients died of the following causes: early medical/surgical complications (n = 3), sepsis (n = 1), catheter-related complication (n = 1), aneurysmal bleeding (n = 1), second brain tumor (n = 1), and progression (n = 1). Surgery was the only intervention for 5 of 9 survivors. Extent of resection, but neither Ki67 labeling index nor adjuvant therapy, was significantly associated with survival. Chronic complications included neuroendocrine (n = 8), visual (n = 4), and neurodevelopmental (n = 3) deficits. Sixteen pituitary blastomas were attributed to DICER1 abnormalities. CONCLUSIONS: Pituitary blastoma is a locally destructive tumor associated with high mortality. Surgical resection alone provides long-term disease control for some patients. Quality survival is possible with long-term neuroendocrine management.
引用
- Liu APY, Kelsey MM, Sabbaghian N, et al. Clinical Outcomes and Complications of Pituitary Blastoma. J Clin Endocrinol Metab. 2021. PMID: 33236116. doi:10.1210/clinem/dgaa857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。